search
Back to results

Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome

Primary Purpose

Acute Coronary Syndrome

Status
Withdrawn
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Wear an actigraph
Use the mobile application CardiCare™ and wear an actigraph
Sponsored by
Ad scientiam
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Acute Coronary Syndrome focused on measuring CardiCare, Coronary heart disease, Application, Mobile, Acute coronary syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects ≥ 18 years old.
  • Diagnosis of an Acute Coronary Syndrome in the last 3 months, documented by angiographically-proven coronary artery disease or hospitalisation report.
  • Graduated from a phase 2 cardiac rehabilitation, ready to enter a phase 3 CR at home.
  • Having agreed to perform a cardiopulmonary exercise testing and blood count at the inclusion or having performed a cardiopulmonary exercise testing and blood count within the last week.
  • Owning a personal smartphone (Android 5.0 or beyond / iPhone 5s and newer supporting IOS 12 and beyond) with Wifi or a data plan (3G/4G).
  • Able to use a smartphone (e.g. no vision, hearing, cognitive or dexterity impairment).
  • Having agreed to install CardiCare™ application on their own smartphone.
  • Having agreed to wear an actigraph at all times and install the actigraph application (CenterPoint Sync) on their smartphone.
  • Enrolled in or benefiting of a national health system.
  • Having read the information sheet and signed the informed consent form.

Non-inclusion Criteria:

  • Treated with Coronary Artery Bypass Grafting.
  • Cardiac surgery in the last 12 weeks.
  • Planned revascularisation or surgery in the next 6 months.
  • Clinical heart failure or Left Ventricular Ejection Fraction < 40% documented within the last 2 months.
  • Severe valvular disease.
  • Severe pulmonary disease.
  • Chronic kidney disease (stages III-V).
  • Drug or/and alcohol abuse (as per clinician's judgment).
  • Unstable angina.
  • Osteoarticular condition or other reasons that limit exercise for more than 4 months (clinician's judgment).
  • Uncontrolled hypertension (resting Diastolic BP>100 mmHg and resting Systolic BP >200 mmHg).
  • Severe/uncontrolled arrhythmia.
  • Systemic medical diseases that are likely to affect cognitive functioning.
  • Pregnant women confirmed by a pregnancy test at the inclusion.
  • Participation to another interventional clinical trial (category 1).
  • Illiterate or not proficient in the language of the study country (French, Italian, Spanish or Portuguese according to the country).
  • Person under guardianship or curatorship.

Sites / Locations

  • Corentin Celton hospital
  • Lariboisière hospital
  • Saint-Yves clinic
  • Brie Cardiac Readaptation Centre
  • Maugeri Scientific Clinical Institutes
  • Scientific Institute of Hospitalization and Care San Raffaele Pisana
  • CHOL - Santa Cruz hospital
  • CHULN - Santa Marta hospital
  • Carlos III - La Paz Hospital
  • Santiago University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Group A: standard of care

Group B: standard of care + mobile application CardiCare™

Arm Description

The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.

The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™

Outcomes

Primary Outcome Measures

To evaluate the efficacy at 6 months of CardiCare™ in stabilising or improving the Cardiorespiratory Fitness of patients after acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program, versus standard care.
Proportion of participants with stabilised or improved VO2max 6 months, as measured by Cardiopulmonary Exercise Test in group B versus group A

Secondary Outcome Measures

To evaluate CardiCare™ impact on global physical activity between both groups over time of follow-up.
The global physical activity will be monitored using continuous variables of the actigraph
To evaluate CardiCare™ impact on change in cardiorespiratory fitness at 3 months versus baseline in both groups.
Proportion of participants in group B versus group A with stabilised or improved VO2max at 3 months compared to baseline.
To evaluate CardiCare™ impact on change in other cardiorespiratory fitness parameters at 3 and 6 months versus baseline, in both groups
Comparison in continous measurement of cardiorespiratory fitness as measured by Cardiopulmonary Exercise Test
To evaluate CardiCare™ impact on change in lipid levels at 3 and 6 months versus baseline, in both groups.
Identification of items will be based in continuous measurement of total cholesterol, Low Density Lipoproteins Cholesterol, High Density lipoproteins Cholesterol.
To evaluate CardiCare™ impact on change in glucose levels at 3 and 6 months versus baseline, in both groups.
Identification of items will be based in continuous measurement of fasting glucose
To evaluate CardiCare™ impact on change in weight at 3 months and 6 months versus baseline in both groups.
Identification of items will be based on measured clinical exam
To evaluate CardiCare™ impact on change in Body Mass Index at 3 months and 6 months versus baseline in both groups.
Identification of items will be based on measured clinical exam
To evaluate CardiCare™ impact on change in Hip and waist circumference at 3 months and 6 months versus baseline in both groups.
Identification of items will be based on measured clinical exam
To evaluate the impact of CardiCare™ on anxiety at 3 and 6 months versus baseline, in both groups.
Identification of the items will be measure with Hospital Anxiety and Depression Scale questionnaires
To evaluate the impact of CardiCare™ on quality of life at 3 and 6 months versus baseline, in both groups.
Identification of the items will be measure with Health-Related Quality of Life questionnaires
To evaluate medication compliance in both groups.
Compliance will based on the duration of medication interruption.
To compare differences of reported cardiovascular events at 3 and 6 months, in both groups.
Comparison will based on the number of cardiovascular events occured
To compare time to first hospital readmission among both groups (all-cause, cardiac, and noncardiac) and their predictors.
Comparison will based on the number of hospital readmission
To assess the cost-effectiveness to reduce 30-day, 3 months and 6 months readmission rates using CardiCare™ as an intervention compared to standard care.
Identification of the items based on the number of hospital readmission
To evaluate the impact of CardiCare™ on employment status at 3 and 6 months versus baseline in both groups.
Identification of the items will based on the time to return to work and the time in sick leave
To evaluate CardiCare™ impact on exercise performed in group B.
Comparison of the exercise performed during the follow up of participants in group B.
To evaluate CardiCare™ impact on cardiovascular risk factors control at 3 and 6 months versus baseline in both groups.
Identification of the cardiovascular risk factors will based on the clinical exam and blood tests
To evaluate, for each session, the correlation between self-reported physical activities in CardiCare™ and those collected by the actigraph in group B.
Identification of items will be based on the physical activities reported by the patient in CardiCare™ and actigraph
To identify patterns of VO2max evolution between D0, M3 and M6, between both groups
Identification of items will be based on the measures of cardiorespiratory fitness as measured by Cardiopulmonary Exercise Test
To evaluate CardiCare™ impact on sleep quality between groups over time of follow-up.
Identification of the items be based on actigraph
To evaluate the safety of the CardiCare™ use.
Safety will be assessed by the numbers of adverse events and adverse events related to the use of the application CardiCare™.
To collect patients and investigators feedback on the CardiCare™ application.
Descriptive analysis of patients and investigators satisfaction related to the mobile application.

Full Information

First Posted
February 25, 2020
Last Updated
June 24, 2021
Sponsor
Ad scientiam
search

1. Study Identification

Unique Protocol Identification Number
NCT04294940
Brief Title
Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome
Official Title
Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Study suspended due to the COVID-19 pandemic. Some study procedures are not curently possible for many investigational sites.
Study Start Date
December 2021 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ad scientiam

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Coronary heart disease is a partial inability of the coronary arteries to supply the heart muscle due to their narrowing. There is angina and myocardial infarction. Coronary heart disease is the first cause of non-communicated deaths and years of life lost. After hospital discharge, a few days following the acute care of a coronary heart disease, a formal Cardiac Rehabilitation programme (CR) is usually provided. CR is a comprehensive programme involving exercise training, risk factor modification, education and psychological support. It is generally sequenced in 4 phases. Phase 1 begins at the hospital and consists of early mobilisation and education. Most phase 2 CR models are based upon supervised ambulatory outpatient programmes. Maintenance (phase 3 and 4) follows the ambulatory programme in which physical fitness and risk factor control are supported in a minimally supervised setting. Despite high-grade recommendations and abundant clinical evidence, a CR program is not always implemented and the patients are not systematically referred after discharge from a phase 1 CR. Furthermore, compliance to pharmacological treatments and changes in lifestyle and diet are hugely neglected following a phase 2 CR and an important number of patients resume a sedentary lifestyle. A growing body of evidence supports the use of digital tools such as smartphones and tablets in helping the patients achieve their goals in terms of physical exercise, risk-factor reduction and diet improvement. Ad Scientiam has developed CardiCare™, a mobile application intended to provide a personalised physical training plan contributing to stabilise or improve cardiorespiratory fitness through improvement of VO2max. The mobile application CardiCare™ is to be used by patients after an acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program in a cardiac rehabilitation centre and entering in phase 3 CR. The mobile application CardiCare™ consists of several modules: A physical activity recommendation engine, providing personalised weekly activity schedule, self-adapting to the patient's clinical characteristics, physical capacity and sport preferences through a proprietary algorithm Self-administered questionnaires to assess perceived exertion, chest pain, weight variations, patient's quality of life Passive monitoring of the patient's physical activity through Apple's HealthKit and Google's Fit Informational content about cardiovascular diseases, risk factor reduction and chest pain action plan The investigator's work hypothesis is that, compared to standard care, CardiCare™ will stabilise or improve the cardiorespiratory fitness (VO2max) acquired post-CR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome
Keywords
CardiCare, Coronary heart disease, Application, Mobile, Acute coronary syndrome

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A: standard of care
Arm Type
Other
Arm Description
The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
Arm Title
Group B: standard of care + mobile application CardiCare™
Arm Type
Other
Arm Description
The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
Intervention Type
Other
Intervention Name(s)
Wear an actigraph
Intervention Description
Between visits, tha patient will have to: Follow the hygiene-dietetic recommendations given by their centre. Wear the actigraph night and day Patients
Intervention Type
Other
Intervention Name(s)
Use the mobile application CardiCare™ and wear an actigraph
Intervention Description
Between visits, tha patient will have to: Follow the hygiene-dietetic recommendations given by their centre. Wear the actigraph night and day Patients wear their smartphone everyday and use the mobile application CardiCare™
Primary Outcome Measure Information:
Title
To evaluate the efficacy at 6 months of CardiCare™ in stabilising or improving the Cardiorespiratory Fitness of patients after acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program, versus standard care.
Description
Proportion of participants with stabilised or improved VO2max 6 months, as measured by Cardiopulmonary Exercise Test in group B versus group A
Time Frame
From day 0 to month 6
Secondary Outcome Measure Information:
Title
To evaluate CardiCare™ impact on global physical activity between both groups over time of follow-up.
Description
The global physical activity will be monitored using continuous variables of the actigraph
Time Frame
From day 0 to month 6
Title
To evaluate CardiCare™ impact on change in cardiorespiratory fitness at 3 months versus baseline in both groups.
Description
Proportion of participants in group B versus group A with stabilised or improved VO2max at 3 months compared to baseline.
Time Frame
From day 0 to month 3
Title
To evaluate CardiCare™ impact on change in other cardiorespiratory fitness parameters at 3 and 6 months versus baseline, in both groups
Description
Comparison in continous measurement of cardiorespiratory fitness as measured by Cardiopulmonary Exercise Test
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on change in lipid levels at 3 and 6 months versus baseline, in both groups.
Description
Identification of items will be based in continuous measurement of total cholesterol, Low Density Lipoproteins Cholesterol, High Density lipoproteins Cholesterol.
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on change in glucose levels at 3 and 6 months versus baseline, in both groups.
Description
Identification of items will be based in continuous measurement of fasting glucose
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on change in weight at 3 months and 6 months versus baseline in both groups.
Description
Identification of items will be based on measured clinical exam
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on change in Body Mass Index at 3 months and 6 months versus baseline in both groups.
Description
Identification of items will be based on measured clinical exam
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on change in Hip and waist circumference at 3 months and 6 months versus baseline in both groups.
Description
Identification of items will be based on measured clinical exam
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate the impact of CardiCare™ on anxiety at 3 and 6 months versus baseline, in both groups.
Description
Identification of the items will be measure with Hospital Anxiety and Depression Scale questionnaires
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate the impact of CardiCare™ on quality of life at 3 and 6 months versus baseline, in both groups.
Description
Identification of the items will be measure with Health-Related Quality of Life questionnaires
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate medication compliance in both groups.
Description
Compliance will based on the duration of medication interruption.
Time Frame
From day 0 to month 6
Title
To compare differences of reported cardiovascular events at 3 and 6 months, in both groups.
Description
Comparison will based on the number of cardiovascular events occured
Time Frame
From day 0 to month 3 and month 6
Title
To compare time to first hospital readmission among both groups (all-cause, cardiac, and noncardiac) and their predictors.
Description
Comparison will based on the number of hospital readmission
Time Frame
From day 0 to month 3 and month 6
Title
To assess the cost-effectiveness to reduce 30-day, 3 months and 6 months readmission rates using CardiCare™ as an intervention compared to standard care.
Description
Identification of the items based on the number of hospital readmission
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate the impact of CardiCare™ on employment status at 3 and 6 months versus baseline in both groups.
Description
Identification of the items will based on the time to return to work and the time in sick leave
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on exercise performed in group B.
Description
Comparison of the exercise performed during the follow up of participants in group B.
Time Frame
From day 0 to month 6
Title
To evaluate CardiCare™ impact on cardiovascular risk factors control at 3 and 6 months versus baseline in both groups.
Description
Identification of the cardiovascular risk factors will based on the clinical exam and blood tests
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate, for each session, the correlation between self-reported physical activities in CardiCare™ and those collected by the actigraph in group B.
Description
Identification of items will be based on the physical activities reported by the patient in CardiCare™ and actigraph
Time Frame
From day 0 to month 6
Title
To identify patterns of VO2max evolution between D0, M3 and M6, between both groups
Description
Identification of items will be based on the measures of cardiorespiratory fitness as measured by Cardiopulmonary Exercise Test
Time Frame
From day 0 to month 3 and month 6
Title
To evaluate CardiCare™ impact on sleep quality between groups over time of follow-up.
Description
Identification of the items be based on actigraph
Time Frame
From day 0 to month 6
Title
To evaluate the safety of the CardiCare™ use.
Description
Safety will be assessed by the numbers of adverse events and adverse events related to the use of the application CardiCare™.
Time Frame
From day 0 to month 6
Title
To collect patients and investigators feedback on the CardiCare™ application.
Description
Descriptive analysis of patients and investigators satisfaction related to the mobile application.
Time Frame
From day 0 to month 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects ≥ 18 years old. Diagnosis of an Acute Coronary Syndrome in the last 3 months, documented by angiographically-proven coronary artery disease or hospitalisation report. Graduated from a phase 2 cardiac rehabilitation, ready to enter a phase 3 CR at home. Having agreed to perform a cardiopulmonary exercise testing and blood count at the inclusion or having performed a cardiopulmonary exercise testing and blood count within the last week. Owning a personal smartphone (Android 5.0 or beyond / iPhone 5s and newer supporting IOS 12 and beyond) with Wifi or a data plan (3G/4G). Able to use a smartphone (e.g. no vision, hearing, cognitive or dexterity impairment). Having agreed to install CardiCare™ application on their own smartphone. Having agreed to wear an actigraph at all times and install the actigraph application (CenterPoint Sync) on their smartphone. Enrolled in or benefiting of a national health system. Having read the information sheet and signed the informed consent form. Non-inclusion Criteria: Treated with Coronary Artery Bypass Grafting. Cardiac surgery in the last 12 weeks. Planned revascularisation or surgery in the next 6 months. Clinical heart failure or Left Ventricular Ejection Fraction < 40% documented within the last 2 months. Severe valvular disease. Severe pulmonary disease. Chronic kidney disease (stages III-V). Drug or/and alcohol abuse (as per clinician's judgment). Unstable angina. Osteoarticular condition or other reasons that limit exercise for more than 4 months (clinician's judgment). Uncontrolled hypertension (resting Diastolic BP>100 mmHg and resting Systolic BP >200 mmHg). Severe/uncontrolled arrhythmia. Systemic medical diseases that are likely to affect cognitive functioning. Pregnant women confirmed by a pregnancy test at the inclusion. Participation to another interventional clinical trial (category 1). Illiterate or not proficient in the language of the study country (French, Italian, Spanish or Portuguese according to the country). Person under guardianship or curatorship.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alain Cohen Solal, Prof
Organizational Affiliation
Lariboisière Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Corentin Celton hospital
City
Issy les Moulineaux
Country
France
Facility Name
Lariboisière hospital
City
Paris
Country
France
Facility Name
Saint-Yves clinic
City
Rennes
Country
France
Facility Name
Brie Cardiac Readaptation Centre
City
Villeneuve-Saint-Denis
Country
France
Facility Name
Maugeri Scientific Clinical Institutes
City
Pavia
Country
Italy
Facility Name
Scientific Institute of Hospitalization and Care San Raffaele Pisana
City
Roma
Country
Italy
Facility Name
CHOL - Santa Cruz hospital
City
Carnaxide
Country
Portugal
Facility Name
CHULN - Santa Marta hospital
City
Lisboa
Country
Portugal
Facility Name
Carlos III - La Paz Hospital
City
Madrid
Country
Spain
Facility Name
Santiago University Hospital
City
Santiago De Compostela
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
34741536
Citation
Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4.
Results Reference
derived

Learn more about this trial

Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome

We'll reach out to this number within 24 hrs